CORDIS
EU research results

CORDIS

English EN
Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Objective

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 281 528,92

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

MAST CARBON INTERNATIONAL LTD

United Kingdom

EU Contribution

€ 398 495,13

ALPHA BIORESEARCH SL

Spain

EU Contribution

€ 764 535,66

UNIVERSITY OF BRIGHTON

United Kingdom

EU Contribution

€ 179 954,98

A2F ASSOCIATES LIMITED

United Kingdom

EU Contribution

€ 134 936,30

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 292 056,21

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

EU Contribution

€ 261 399,59

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Spain

EU Contribution

€ 289 320,16

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 290 506,83

FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Portugal

EU Contribution

€ 307 182,81

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 278 148,33

UNIVERSITAET BERN

Switzerland

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 297 016,21

YAQRIT LIMITED

United Kingdom

EU Contribution

€ 899 748,62

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)

Spain

EU Contribution

€ 238 250

Project information

Grant agreement ID: 634579

Status

Ongoing project

  • Start date

    1 May 2015

  • End date

    31 October 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 438 786,13

  • EU contribution

    € 5 913 079,75

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom